Wednesday, September 03, 2025
Biopharma companies advancing cell therapies must confront a range of key considerations and risks. A strategic, collaborative approach can accelerate development and ensure patients reliably access safe and effective cell therapy products.
As logic-gated CAR-Ts advance into human studies, the field is moving toward multi-layered platforms that integrate Boolean logic, microenvironmental sensing, enhanced trafficking, and dynamic control of T-cell behavior, with the goal of delivering safer, more durable, and scalable therapies for solid tumors.